ECM
BMY.RT

Evergreen Capital Management’s Bristol-Myers Squibb Company Contingent Value Rights BMY.RT Stock Holding History

Evergreen Capital Management’s Portfolio BMY.RT Stock Details BMY.RT Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2021
Q1 		– Sell
-34,094
Closed -$24K – 525
2020
Q4 		$24K Sell
34,094
-802
-2% -$1.71K ﹤0.01% 449
2020
Q3 		$79K Sell
34,896
-1,286
-4% -$3.67K 0.01% 412
2020
Q2 		$130K Sell
36,182
-1,520
-4% -$5.48K 0.01% 375
2020
Q1 		$143K Sell
37,702
-1,291
-3% -$4.25K 0.01% 342
2019
Q4 		$117K Buy
+38,993
New +$101K 0.01% 455

Other funds holding BMY.RT

JCI
Jet Capital Investors New York $51M AUM 48.01% 1-Year Est. Return
Tudor Investment Corp
Tudor Investment Corp Stamford, Connecticut $53.9B AUM 29.12% 1-Year Est. Return
BC
Brookfield Corp Toronto, Ontario, Canada $74.2B AUM 0.68% 1-Year Est. Return
TNB
Thomasville National Bank Thomasville, Georgia $1.61B AUM 22.15% 1-Year Est. Return
WAM
Westport Asset Management Southport, Connecticut $226M AUM 16.76% 1-Year Est. Return
IAIM
International Assets Investment Management Orlando, Florida $1.44B AUM 21.92% 1-Year Est. Return

Evergreen Capital Management's BMY.RT Position: Q1 2021 in Review

Evergreen Capital Management sold out of Bristol-Myers Squibb Company Contingent Value Rights (BMY.RT) in Q1 2021, closing a stake of 34,094 shares — an estimated $24K sold.

Evergreen Capital Management first reported a position in BMY.RT in Q4 2019 and held it in 5 quarters. The position peaked at $143K in Q1 2020. 12 funds tracked by Wall St. Rank hold BMY.RT as of Q1 2021.

  • Evergreen Capital Management reported no remaining Bristol-Myers Squibb Company Contingent Value Rights position as of Q1 2021 after selling out during the quarter.
  • Evergreen Capital Management sold 34,094 Bristol-Myers Squibb Company Contingent Value Rights shares in Q1 2021, an estimated $24K.
  • Evergreen Capital Management first reported a position in Bristol-Myers Squibb Company Contingent Value Rights in Q4 2019 and held it in 5 quarters.
  • Evergreen Capital Management's Bristol-Myers Squibb Company Contingent Value Rights position peaked at $143K in Q1 2020.
  • 12 funds tracked by Wall St. Rank held Bristol-Myers Squibb Company Contingent Value Rights as of Q1 2021.

Based on Evergreen Capital Management's 13F filing for Q1 2021, filed 17 May 2021.